
Please try another search
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Name | Age | Since | Title |
---|---|---|---|
Kenneth S. Lin | 51 | 2021 | Lead Independent Director |
Areta L. Kupchyk | 66 | 2021 | Independent Director |
Andrew Monte | - | 2021 | Member of Scientific Advisory Board |
Arjun Chanmugam | - | 2021 | Member of Scientific Advisory Board |
Joseph F. Lawler | 52 | 2020 | Founder & Chairman |
Bimal R. Shah | - | 2023 | Independent Director |
Richard Anthony Cunningham | 53 | 2023 | CEO & Director |
Aron R. English | 42 | 2020 | Independent Director |
Jason M. Aryeh | 56 | 2021 | Independent Director |
Nathaniel Calloway | 41 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review